Latest news with #1MainCapital
Yahoo
03-05-2025
- Business
- Yahoo
Here's Why Third Harmonic Bio (THRD) Fell in Q1
1 Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned (3.6)% net in the first quarter compared to (4.3)% and (9.5)% for the S&P 500 (SPX) and Russell 2000 (RTY). Since its inception in February 2018, the fund has returned annualized net returns of 19.5%, compared to 11.9% and 4.8% for the indexes. In addition, you can check the fund's top 5 holdings to find out its best picks for 2025. In its first-quarter 2025 investor letter, 1 Main Capital highlighted stocks such as Third Harmonic Bio, Inc. (NASDAQ:THRD). Third Harmonic Bio, Inc. (NASDAQ:THRD) is a biopharmaceutical company. The one-month return of Third Harmonic Bio, Inc. (NASDAQ:THRD) was 48.28%, and its shares lost 55.90% of their value over the last 52 weeks. On May 1, 2025, Third Harmonic Bio, Inc. (NASDAQ:THRD) stock closed at $5.16 per share with a market capitalization of $232.76 million. 1 Main Capital stated the following regarding Third Harmonic Bio, Inc. (NASDAQ:THRD) in its Q1 2025 investor letter: "Third Harmonic Bio, Inc. (NASDAQ:THRD) came public in 2022, and its shares quickly came under pressure after the company reported that THB001, its primary drug, caused liver toxicity issues in trials. In February 2025, phase 1 data for another pipeline asset, THB335 ('335'), also disappointed investors. A close-up of a microscope, revealing the details of a small-molecule KIT inhibitor. Third Harmonic Bio, Inc. (NASDAQ:THRD) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held Third Harmonic Bio, Inc. (NASDAQ:THRD) at the end of the fourth quarter, compared to 16 in the third quarter. While we acknowledge the potential of Third Harmonic Bio, Inc. (NASDAQ:THRD) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
02-05-2025
- Business
- Yahoo
Here are 1 Main Capital Partners' Views on Arvinas (ARVN)
1 Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned (3.6)% net in the first quarter compared to (4.3)% and (9.5)% for the S&P 500 (SPX) and Russell 2000 (RTY). Since its inception in February 2018, the fund has returned annualized net returns of 19.5%, compared to 11.9% and 4.8% for the indexes. In addition, you can check the fund's top 5 holdings to find out its best picks for 2025. In its first-quarter 2025 investor letter, 1 Main Capital highlighted stocks such as Arvinas, Inc. (NASDAQ:ARVN). Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company. The one-month return of Arvinas, Inc. (NASDAQ:ARVN) was 4.78%, and its shares lost 77.71% of their value over the last 52 weeks. On May 1, 2025, Arvinas, Inc. (NASDAQ:ARVN) stock closed at $7.23 per share with a market capitalization of $527.728 million. 1 Main Capital stated the following regarding Arvinas, Inc. (NASDAQ:ARVN) in its Q1 2025 investor letter: "Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotech company developing targeted protein degraders, is down more than 90% from its 2021 highs due to investor disappointment with its trials. A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. Arvinas, Inc. (NASDAQ:ARVN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held Arvinas, Inc. (NASDAQ:ARVN) at the end of the fourth quarter, compared to 34 in the third quarter. While we acknowledge the potential of Arvinas, Inc. (NASDAQ:ARVN) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Arvinas, Inc. (NASDAQ:ARVN) and shared the list of stocks under $10 that will triple. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
